Advanced search
Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 36, 2023 - Issue 2
Submit an article Journal homepage
49
Views
0
CrossRef citations to date
0
Altmetric
Original Research: COVID-19

Real-world effectiveness of COVID-19 vaccination in liver cirrhosis: a systematic review with meta-analysis of 51,834 patients

Azizullah Berana Division of Gastroenterology and Hepatology, Indiana University, Indianapolis, IndianaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-4161-942X
, MDORCID Icon,
Asmaa Mhannab Department of Pediatrics, ProMedica Hospital, Toledo, Ohio
, MD,
Mohammed Mhannac Division of Cardiology, University of Iowa, Iowa City, Iowa
, MD, MPH,
Ramzi Hassouneha Division of Gastroenterology and Hepatology, Indiana University, Indianapolis, Indiana
, DO,
Ziad Abuhelwad Department of Internal Medicine, University of Toledo, Toledo, Ohio
, MD,
Mouhand F. H. Mohamede Department of Internal Medicine, Warren Alpert Medical School, Brown University, Providence, Rhode Island
, MD, MSc,
Wasef Sayehd Department of Internal Medicine, University of Toledo, Toledo, Ohio
, MD,
Rami Musallamf Department of Internal Medicine, St. Vincent Charity Medical Center, Cleveland, Ohio
, MD,
Ragheb Assalyd Department of Internal Medicine, University of Toledo, Toledo, Ohio
, MD &
Khaled Abdeljawada Division of Gastroenterology and Hepatology, Indiana University, Indianapolis, Indiana
, MD show all
Pages 151-156 | Received 21 Sep 2022, Accepted 17 Dec 2022, Published online: 17 Jan 2023

  • Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110–118. doi:10.1016/j.jaci.2020.04.006.
  • Tenforde MW, Self WH, Adams K, et al. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA. 2021;326(20):2043–2054. doi:10.1001/jama.2021.19499.
  • Ioannou GN, Liang PS, Locke E, et al. Cirrhosis and severe acute respiratory syndrome coronavirus 2 infection in US veterans: risk of infection, hospitalization, ventilation, and mortality. Hepatology. 2021;74(1):322–335. doi:10.1002/hep.31649.
  • Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416. doi:10.1056/NEJMoa2035389.
  • Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi:10.1056/NEJMoa2034577.
  • Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111. doi:10.1016/S0140-6736(20)32661-1.
  • Sharma A, Patnaik I, Kumar A, Gupta R. COVID-19 vaccines in patients with chronic liver disease. J Clin Exp Hepatol. 2021;11(6):720–726. doi:10.1016/j.jceh.2021.06.013.
  • Noor MT, Manoria P. Immune dysfunction in cirrhosis. J Clin Transl Hepatol. 2017;5(1):50–58. doi:10.14218/JCTH.2016.00056.
  • Ruether DF, Schaub GM, Duengelhoef PM, et al. SARS-CoV2-specific humoral and T-cell immune response after second vaccination in liver cirrhosis and transplant patients. Clin Gastroenterol Hepatol. 2022;20(1):162–172.e169. doi:10.1016/j.cgh.2021.09.003.
  • John BV, Deng Y, Scheinberg A, et al. Association of BNT162b2 mRNA and mRNA-1273 vaccines with COVID-19 infection and hospitalization among patients with cirrhosis. JAMA Intern Med. 2021;181(10):1306–1314. doi:10.1001/jamainternmed.2021.4325.
  • John BV, Deng Y, Schwartz KB, et al. Postvaccination COVID-19 infection is associated with reduced mortality in patients with cirrhosis. Hepatology. 2022;76(1):126–138. doi:10.1002/hep.32337.
  • Moon AM, Webb GJ, García-Juárez I, et al. SARS-CoV-2 infections among patients with liver disease and liver transplantation who received COVID-19 vaccination. Hepatol Commun. 2022;6(4):889–897. doi:10.1002/hep4.1853.
  • Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71.
  • Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785–1805. doi:10.1177/0962280216669183.
  • Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1(2):97–111. doi:10.1002/jrsm.12.
  • Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560. doi:10.1136/bmj.327.7414.557.
  • Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605. doi:10.1007/s10654-010-9491-z.
  • Ge J, Digitale JC, Pletcher MJ, Lai JC, for the N3C Consortium. Breakthrough SARS-CoV-2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: A National COVID Cohort Collaborative study. Hepatology. 2022;1–17. doi:10.1002/hep.32780.
  • Bressler S, Chang G, Birhane M, et al. COVID-19 vaccine breakthrough infections reported to CDC—United States, January 1–April 30, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(21):792–793.
  • Ge J, Pletcher MJ, Lai JC, Outcomes of SARS-CoV-2 infection in patients with chronic liver disease and cirrhosis: a national COVID Cohort Collaborative Study. Gastroenterology. 2021;161(5):1487–1501.e5. e1485. doi:10.1053/j.gastro.2021.07.010.
  • Cornberg M, Buti M, Eberhardt CS, Grossi PA, Shouval D. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. J Hepatol. 2021;74(4):944–951. doi:10.1016/j.jhep.2021.01.032.
  • Fix OK, Blumberg EA, Chang KM, et al. American Association for the Study of Liver Diseases expert panel consensus statement: vaccines to prevent coronavirus disease 2019 infection in patients with liver disease. Hepatology. 2021;74(2):1049–1064. doi:10.1002/hep.31751.
  • Cao Z, Zhang C, Zhao S, et al. COVID-19 vaccines in patients with decompensated cirrhosis: a retrospective cohort on safety data and risk factors associated with unvaccinated status. Infect Dis Poverty. 2022;11(1):56. doi:10.1186/s40249-022-00982-0.
  • Marjot T, Webb GJ, Barritt AS, et al. SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question. Lancet Gastroenterol Hepatol. 2021;6(3):156–158. doi:10.1016/S2468-1253(21)00008-X.
  • Willuweit K, Frey A, Passenberg M, et al. Patients with liver cirrhosis show high immunogenicity upon COVID-19 vaccination but develop premature deterioration of antibody titers. Vaccines (Basel). 2022;10(3):377. doi:10.3390/vaccines10030377.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.